September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Restasis® prevents lacrimal gland pathology in the novel SiccaSystemTM standardized experimental platform for experimental dry-eye disease research
Author Affiliations & Notes
  • Agne Ziniauskaite
    Experimentica, Kuopio, Finland
  • Symantas Ragauskas
    Experimentica, Kuopio, Finland
  • Jooseppi Puranen
    Experimentica, Kuopio, Finland
  • Anne Mari Haapaniemi
    Experimentica, Kuopio, Finland
  • Giedrius Kalesnykas
    Experimentica, Kuopio, Finland
  • Simon Kaja
    K&P Scientific LLC, Hines, Illinois, United States
    Ophthalmology, Loyola University Chicago, Maywood, Illinois, United States
  • Footnotes
    Commercial Relationships   Agne Ziniauskaite, Experimentica Ltd (E); Symantas Ragauskas, Experimentica Ltd (E); Jooseppi Puranen, Experimentica Ltd (E); Anne Mari Haapaniemi, Experimentica Ltd (E); Giedrius Kalesnykas, Experimentica Ltd (E), Experimentica Ltd (I), Experimentica Ltd (S); Simon Kaja, Experimentica Ltd (R), Experimentica Ltd (F), Experimentica Ltd (C), Experimentica Ltd (P), Experimentica Ltd (I), Experimentica Ltd (S), K&P Scientific LLC (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5690. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Agne Ziniauskaite, Symantas Ragauskas, Jooseppi Puranen, Anne Mari Haapaniemi, Giedrius Kalesnykas, Simon Kaja; Restasis® prevents lacrimal gland pathology in the novel SiccaSystemTM standardized experimental platform for experimental dry-eye disease research. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5690.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Dry eye syndrome (Keratoconjunctivitis sicca; KCS) is a multifactorial disease of the tear glands and ocular surface. Currently available treatments are only partially effective and novel strategies for KCS pharmacotherapy are urgently needed. However, advances in the development of anti-KCS drugs are hindered by a lack of standardized and validated desiccating environment chambers.

Methods : Experimental KCS was induced in 6 week-old C57BL/6 mice by exposure to a novel desiccating environment chamber (SiccaSystemTM, K&P Scientific LLC, Hines, IL) and concurrent transdermal administration of scopolamine for 10 days. Air flow and humidity were set at 15 L/min and 5%, respectively. In order to validate the SiccaSystemTM chamber, one group of mice was treated with Restasis® (0.05% Cyclosporine Ophthalmic Emulsion, Allergan, Irvine, CA), applied topically as eye drops twice daily into the right eye; the left eye served as untreated control. We quantified lacrimal gland pathology and severity of KCS symptoms by grading the extent of mononuclear cell infiltration in the lacrimal gland and quantification of corneal epithelial thickness, goblet cell number and tear volume.

Results : Exposure to the SiccaSystemTM desiccating environment with concurrent scopolamine administration resulted in significant focal accumulation of mononuclear cells in the lacrimal gland and notable parenchymal damage. Thickness of the conjunctival epithelium increased from 16.3 µm to 19.60 µm (P<0.05), while tear volume was reduced by 50% (P<0.05). Topical administration of Restasis® significantly improved lacrimal gland pathology compared to control eyes.

Conclusions : We developed and successfully validated the SiccaSystemTM desiccating environment chamber. Restasis®, the only currently FDA-approved drug for KCS, showed efficacy against lacrimal gland damage and other quantitative KCS readouts, serving as a benchmark for future, novel anti-KCS drugs. In conclusion, the SiccaSystemTM chamber will facilitate development of novel KCS pharmacotherapies by providing a novel validated standardized experimental platform for drug discovery for KCS.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×